Author

D. K. Chang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

A. Biankin· 1 shared A. D. Campbell· 1 shared A. K. Najumudeen· 1 shared B. Sridharan· 1 shared C. A. Ford· 1 shared C. Lee· 1 shared C. Nixon· 1 shared C. V. Leiton· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Biankin

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity

S. K. Fey, A. K. Najumudeen, C. A. Ford, K. Gilroy, R. Upstill-Goddard, W. Clark, C. Nixon, D. K. Chang, S. T. Barry, J. P. Morton, A. D. Campbell, O. J. Sansom

This study shows that loss of wild-type Kras enhances oncogenic Kras signaling and promotes pancreatic ductal adenocarcinoma, while also increasing sensitivity to MEK1/2 inhibitors.

bioRxiv · Aug 29, 2023 · PreprintCancer Biology

Epithelial Regeneration Ability of Crohn's Disease Assessed Using Patient-Derived Intestinal Organoids

C. Lee, S. N. Hong, E. R. Kim, D. K. Chang, Y.-H. Kim

This study assesses epithelial regeneration ability in Crohn's disease using patient-derived intestinal organoids and finds impaired regeneration, especially under TNF treatment.

bioRxiv · Mar 25, 2021Cell Biology

An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer

C.-H. Pan, Y. Otsuka, B. Sridharan, M. Woo, S. Babu, C. V. Leiton, J. D. Bai, D. K. Chang, A. Biankin, L. Scampavia, T. Spicer, L. F. Escobar-Hoyos, K. R. Shroyer

This study identifies K17 as a biomarker for PDAC and shows that PPT, a microtubule inhibitor, is more effective against K17-expressing PDAC cells when combined with Gemcitabine.

bioRxiv · Oct 11, 2019Cancer Biology